Vieweg V, Glick J L, Herring S, Kerler R, Godleski L S, Barber J, Yank G, Spradlin W
Am J Psychiatry. 1987 Jul;144(7):943-7. doi: 10.1176/ajp.144.7.943.
Of 33 chronically psychotic patients in a state hospital, 17 received carbamazepine, 13 received carbamazepine and lithium, and three received carbamazepine and then the combination. There was a significant difference in serum sodium level between the patients receiving carbamazepine alone (mean +/- SD = 138.4 +/- 4.3 meq/liter) and those also receiving lithium (141.8 +/- 1.6 meq/liter). (A similar difference was seen for the patients who received the two treatments serially.) Age, sex, diagnosis, age at diagnosis, seizure disorder, antipsychotic drugs, and serum carbamazepine level did not explain this difference. The protection against hyponatremia provided by the carbamazepine-lithium combination occurred despite lithium's tendency to increase polyuria.
在一家州立医院的33名慢性精神病患者中,17名接受了卡马西平治疗,13名接受了卡马西平和锂盐联合治疗,3名先接受卡马西平治疗,然后再接受联合治疗。单独接受卡马西平治疗的患者(平均±标准差=138.4±4.3毫当量/升)与同时接受锂盐治疗的患者(141.8±1.6毫当量/升)之间的血清钠水平存在显著差异。(先后接受两种治疗的患者也出现了类似差异。)年龄、性别、诊断、诊断时年龄、癫痫障碍、抗精神病药物以及血清卡马西平水平均无法解释这种差异。尽管锂盐有增加多尿的倾向,但卡马西平-锂盐联合治疗对低钠血症仍有预防作用。